The GLP is committed to full transparency. Download and review our 2019 Annual Report

Did California’s $3 billion stem cell bet pay off?

evangelina wide f d b d b b f b d e f ab s c
Evangelina Padilla-Vaccaro, now cured of a serious genetic illness — thanks to a successful stem cell treatment — playing recently in a public park. The bubble around her is just for fun. Image credit: Alysia Padilla-Vaccaro
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

It was an extraordinary political proposal: Approve a $3 billion bond measure to fund the cutting-edge science of stem cell therapy, and soon some of the world’s cruelest diseases and most disabling injuries could be eradicated. The 2004 measure was Proposition 71, the California Stem Cell Research and Cures Initiative.

At UCLA, doctors are using stem cells to cure a rare immune deficiency disease that kills children. At Stanford, early studies show that stem cells deposited deep into the brain could restore movement and speech to people devastated by stroke. At UCSF, a team is beginning human trials for a fatal genetic blood disease that involves transplanting stem cells into a fetus still in the uterus.

Related article:  Religious beliefs shape our thinking on cloning, stem cells and gene editing

But as thrilling as such advances are, they fall far short of what Prop. 71’s promoters promised.

Not a single federally approved therapy has resulted from CIRM-funded science. The predicted financial windfall has not materialized. The bulk of CIRM grants have gone to basic research, training programs and building new laboratories, not to clinical trials testing the kinds of potential cures and therapies the billions of dollars were supposed to deliver.

“What was promised was not deliverable,” said longtime CIRM board member Jeff Sheehy, a former San Francisco supervisor. “However, I would distinguish the promises from the impact and value. We have developed a regenerative medicine juggernaut.”

Read full, original post: Lofty promises, limited results

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend